Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.

ABSTRACT:

Rationale & objective

Urinary biomarkers of injury, inflammation, and repair may help phenotype acute kidney injury (AKI) observed in clinical trials. We evaluated the differences in biomarkers between participants randomized to monotherapy or to combination renin-angiotensin-aldosterone system (RAAS) blockade in VA NEPHRON-D, where an increased proportion of observed AKI was acknowledged in the combination arm.

Study design

Longitudinal analysis.

Setting & participants

A substudy of the VA NEPHRON-D trial.

Predictor

Primary exposure was the treatment arm (combination [RAAS inhibitor] vs monotherapy). AKI is used as a stratifying variable.

Outcome

Urinary biomarkers, including albumin, EGF (epidermal growth factor), MCP-1 (monocyte chemoattractant protei

SUBMITTER: Kiernan EA 

PROVIDER: S-EPMC10841767 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature